prostaglandin A1 (PGA1)

Also Known As:

PGA1; (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dien-1-oic acid; prostaglandin A1, (13E,15R)-(+-)-isomer; prostaglandin A1, (13E,15R)-isomer; prostaglandin A1, (13E,15S)-(+-)-isomer; prostaglandin A1, (8beta,12alpha,13E,15S)-isomer

Networked: 107 relevant articles (6 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Unsaturated Fatty Acids: 8236
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Prostaglandins A: 1719
        prostaglandin A1: 107
Biological Factors: 2472
- Inflammation Mediators: 1113
  - Autacoids: 276
    - Eicosanoids: 3262
      - Prostaglandins: 17100
        Prostaglandins A: 1719
        prostaglandin A1: 107

Experts

1.	Han, Rong: 3 articles (08/2007 - 03/2005)
2.	Guan, Pei-Pei: 2 articles (03/2021 - 01/2019)
3.	Wang, Pu: 2 articles (03/2021 - 01/2019)
4.	Xu, Guo-Biao: 2 articles (03/2021 - 01/2019)
5.	Qin, Zheng-Hong: 2 articles (08/2006 - 03/2005)
6.	Boguś, Mieczysława Irena: 1 article (01/2021)
7.	Kaczmarek, Agata: 1 article (01/2021)
8.	Kazek, Michalina: 1 article (01/2021)
9.	Wrońska, Anna Katarzyna: 1 article (01/2021)
10.	Beldar, Serap: 1 article (01/2020)

Related Diseases

1.	Infections 09/01/1998 - "We also show that, as reported in studies of different virus/host cell models, PGA1 inhibits HIV-1 replication by acting at multiple levels during HIV-1 infection. " 09/01/2018 - "Hep-2 cells infected with MAYV were treated with PGA1 (0.1-6μg/ml) 12h before infection and for different periods post-infection. " 03/01/1996 - "These results demonstrate a co-operative effect of PGA1 and alpha IFN against VSV infection and suggest that alpha IFN can potentiate the cellular response to HSP induction in virus-infected cells." 05/01/1995 - "PGA1, a powerful inhibitor of tumour cell proliferation, can prevent the clonal expansion of HTLV-I-infected cells following acute infection of cord blood-derived mononuclear cells. " 02/01/1993 - "Recipient CBMC were treated with IFN alpha or beta (1000 IU/ml) at the onset of the co-culture with lethally irradiated virus-donor MT-2 cells, followed by multiple treatments with PGA1 (4 micrograms/ml every 4 days, starting on day 0) for 6 weeks post infection (p.i.). "
2.	Neoplasms (Cancer) 04/01/1980 - "In addition to its effect on tumor size, PGA1 was also effective in stimulating both the humoral and cellular components of the immune response. " 04/01/1988 - "Structural identification of prostaglandin A1 biotransformation products from tumor cells." 12/30/1986 - "Tumor cell biotransformation products of prostaglandin A1 with growth inhibitory activity." 06/01/1986 - "of PGA1 at a dose of 40 mg/kg/day resulted in a 20% suppression in tumor growth. " 10/30/1980 - "PGA1 was observed to inhibit the rate of melanoma growth, both as delay in the rate of appearance and decrease in tumor volume. "
3.	Pre-Eclampsia (Preeclampsia) 01/01/1992 - "Such promising data add another important perspective to prostaglandin A1 in severe pre-eclampsia and may open up new avenues for its use in other situations with compromised placental flow." 01/01/1992 - "Improving placental blood flow in pre-eclampsia with prostaglandin A1." 07/01/1988 - "Treatment of preeclampsia with prostaglandin A1." 01/01/1983 - "Twenty one cases of severe pre-eclampsia (in 3 equal groups) received i.v. infusions of PGA1 in a dose range of 0.1-0.5 microgram/kgm/min for 12 - 24 hours and the B.P., uterine activity and FHR were continuously monitored during and for 12 hours following the infusion period. " 11/01/1979 - "Effect of prostaglandin A1 on renal hemodynamics in pregnancy toxemia."
4.	Cognitive Dysfunction 03/01/2021 - "Long-term treatment of tauP301S Tg mice with PGA1 activated PP2A and significantly reduced tau phosphorylation resulting in improvements in cognitive decline in tauP301S Tg mice. " 03/01/2021 - "The effect of inhibiting tau hyperphosphorylation was tested in the Morris maze to determine the inhibitory effects of PGA1 on cognitive decline in tauP301S Tg mice. " 03/01/2021 - "Our data provided new insight into the mechanisms of the ameliorating effects of PGA1 on cognitive decline in tauP301S Tg mice by activating PP2A via a mechanism involving the formation of a Michael adduct with cysteine 377 of PPP2R1A." 01/01/2019 - "Prostaglandin A1 Inhibits the Cognitive Decline of APP/PS1 Transgenic Mice via PPARγ/ABCA1-dependent Cholesterol Efflux Mechanisms." 01/01/2019 - "The actions of PGA1 on the production and deposition of Aβ ultimately improved the cognitive decline of the amyloid precursor protein/presenilin1 (APP/PS1) transgenic mice."
5.	Neurodegenerative Diseases (Neurodegenerative Disease) 04/01/2001 - "In view of its potent neuroprotective activity, PGA1 could prove useful in the treatment of certain neurodegenerative disorders related to excitotoxicity." 04/01/2001 - "Since both these effects could be neuroprotective, the therapeutic potential of PGA1 in neurodegenerative disorders, where excitotoxicity may contribute to pathogenesis, was evaluated in rat striatal neurons exposed to the N-methyl-D-aspartate (NMDA) receptor agonist quinolinic acid (QA). "

Related Drugs and Biologics

1.	prostaglandin A1 (PGA1)
2.	Proteins (Proteins, Gene)
3.	Prostaglandins
4.	RNA (Ribonucleic Acid)
5.	Chloramphenicol O-Acetyltransferase (Chloramphenicol Acetyltransferase)
6.	Dopamine (Intropin)
7.	Amyloid (Amyloid Fibrils)
8.	phorbol
9.	Heat-Shock Proteins (Heat-Shock Protein)
10.	Neuroprotective Agents

Related Therapies and Procedures

1.	Intravenous Administration
2.	Therapeutics
3.	Intraperitoneal Injections
4.	Intravenous Infusions
5.	Drug Therapy (Chemotherapy)